{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:50:53Z","timestamp":1790898653674,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273951"],"award-info":[{"award-number":["82273951"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong High-level new R&D Institute"},{"name":"Guangdong High-level Innovative Research Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41375-026-02925-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:51:42Z","timestamp":1774425102000},"page":"925-933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity"],"prefix":"10.1038","volume":"40","author":[{"given":"Yutong","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruisen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beijing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7540-2626","authenticated-orcid":false,"given":"Hualin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7765-1771","authenticated-orcid":false,"given":"Xiaobei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-001X","authenticated-orcid":false,"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-4065","authenticated-orcid":false,"given":"Tianfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-3697","authenticated-orcid":false,"given":"Yubo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2925_CR1","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1002\/j.1460-2075.1995.tb00185.x","volume":"14","author":"A Devault","year":"1995","unstructured":"Devault A, Martinez AM, Fesquet D, Labb\u00e9 JC, Morin N, Tassan JP, et al. MAT1 (\u2018menage \u00e0 trois\u2019) a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J. 1995;14:5027\u201336.","journal-title":"EMBO J"},{"key":"2925_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:122.","journal-title":"Genome Biol"},{"key":"2925_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/21541264.2018.1553483","volume":"10","author":"RP Fisher","year":"2019","unstructured":"Fisher RP. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription. 2019;10:47\u201356.","journal-title":"Transcription"},{"key":"2925_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50891-z","volume":"15","author":"R D\u00fcster","year":"2024","unstructured":"D\u00fcster R, Anand K, Binder SC, Schmitz M, Gatterdam K, Fisher RP, et al. Structural basis of Cdk7 activation by dual T-loop phosphorylation. Nat Commun. 2024;15:6597.","journal-title":"Nat Commun"},{"key":"2925_CR5","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/j.molcel.2024.05.007","volume":"84","author":"T Velychko","year":"2024","unstructured":"Velychko T, Mohammad E, Ferrer-Vicens I, Parfentev I, Werner M, Studniarek C, et al. CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release. Mol Cell. 2024;84:2287\u20132303.e10.","journal-title":"Mol Cell"},{"key":"2925_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020;39:805\u201323.","journal-title":"Cancer Metastasis Rev"},{"key":"2925_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 2020;10:351\u201370.","journal-title":"Cancer Discov"},{"key":"2925_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564\u2013576.e16.","journal-title":"Cell"},{"key":"2925_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood.2024026388","volume":"145","author":"W Fiskus","year":"2025","unstructured":"Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, et al. Preclinical efficacy of CDK7 inhibitor\u2013based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025;145:612\u201324.","journal-title":"Blood"},{"key":"2925_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/10428194.2023.2169045","volume":"64","author":"S Zhang","year":"2023","unstructured":"Zhang S, Feng R, Bai J, Ning S, Xu X, Sun J, et al. CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo. Leuk Lymphoma. 2023;64:639\u201350.","journal-title":"Leuk Lymphoma"},{"key":"2925_CR11","first-page":"2645","volume":"130","author":"K Clark","year":"2017","unstructured":"Clark K, Ainscow E, Peall A, Thomson S, Leishman A, Elaine S, et al. CT7001, a novel orally bio-available cdk7 inhibitor, is highly active in in-vitro and in-vivo models of AML. Blood. 2017;130:2645.","journal-title":"Blood"},{"key":"2925_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11004","volume":"8","author":"B-K Koo","year":"2022","unstructured":"Koo B-K, Choi E-J, Hur E-H, Moon JH, Kim JY, Park H-S, et al. Antileukemic activity of YPN-005, a CDK7 inhibitor, inducing apoptosis through c-MYC and FLT3 suppression in acute myeloid leukemia. Heliyon. 2022;8:e11004.","journal-title":"Heliyon"},{"key":"2925_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/13543776.2023.2195547","volume":"33","author":"M Kovalov\u00e1","year":"2023","unstructured":"Kovalov\u00e1 M, Baraka JP, Mik V, Jorda R, Luo L, Shao H, et al. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-222). Expert Opin Ther Pat. 2023;33:67\u201387.","journal-title":"Expert Opin Ther Pat"},{"key":"2925_CR14","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1039\/D2CS00200K","volume":"51","author":"RG Guenette","year":"2022","unstructured":"Guenette RG, Yang SW, Min J, Pei B, Potts PR. Target and tissue selectivity of PROTAC degraders. Chem Soc Rev. 2022;51:5740\u201356.","journal-title":"Chem Soc Rev"},{"key":"2925_CR15","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/s41375-024-02427-z","volume":"38","author":"KM Sakamoto","year":"2024","unstructured":"Sakamoto KM. Can PROTACs cure Leukemia? Leukemia. 2024;38:2552\u20133.","journal-title":"Leukemia"},{"key":"2925_CR16","doi-asserted-by":"crossref","unstructured":"Gui F, Jiang B, Jiang J, He Z, Tsujino T, Takai T, et al. Acute BRCAness induction and AR pathway blockage through CDK12\/7\/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. Sci Adv. 2025;11:eadu0847.","DOI":"10.1126\/sciadv.adu0847"},{"key":"2925_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116613","volume":"276","author":"W Ji","year":"2024","unstructured":"Ji W, Du G, Jiang J, Lu W, Mills CE, Yuan L, et al. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7). Eur J Med Chem. 2024;276:116613.","journal-title":"Eur J Med Chem"},{"key":"2925_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107319","volume":"147","author":"K Wang","year":"2024","unstructured":"Wang K, Jiang M, Liu H, Meng C, Li M, Lu H. Discovery of novel co-degradation CK1\u03b1 and CDK7\/9 PROTACs with p53 activation for treating acute myeloid leukemia. Bioorg Chem. 2024;147:107319.","journal-title":"Bioorg Chem"},{"key":"2925_CR19","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"2925_CR20","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1021\/acs.jmedchem.2c00257","volume":"65","author":"J Li","year":"2022","unstructured":"Li J, Liu T, Song Y, Wang M, Liu L, Zhu H, et al. Discovery of small-molecule degraders of the CDK9-cyclin T1 complex for targeting transcriptional addiction in prostate cancer. J Med Chem. 2022;65:11034\u201357.","journal-title":"J Med Chem"},{"key":"2925_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.chembiol.2025.03.006","volume":"32","author":"N Kwiatkowski","year":"2025","unstructured":"Kwiatkowski N, Liang T, Sha Z, Collier PN, Yang A, Sathappa M, et al. CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. Cell Chem Biol. 2025;32:556\u201369.e24.","journal-title":"Cell Chem Biol"},{"key":"2925_CR22","doi-asserted-by":"publisher","first-page":"22622","DOI":"10.1021\/jacs.2c09255","volume":"144","author":"Y Xiong","year":"2022","unstructured":"Xiong Y, Zhong Y, Yim H, Yang X, Park K-S, Xie L, et al. Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets. J Am Chem Soc. 2022;144:22622\u201332.","journal-title":"J Am Chem Soc"},{"key":"2925_CR23","unstructured":"Fuhrmann J, Wu H, Fairbrother W. 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-carboxamide derivatives AS VHL inhibitors for the treatment of anemia and cancer. 2022. https:\/\/patentscope2.wipo.int\/search\/en\/detail.jsf?docId=WO2022103411&_cid=JP1-ME5SSH-16090-1 (accessed 10 Aug 2025)."},{"key":"2925_CR24","doi-asserted-by":"crossref","unstructured":"Wang H, Xu J-Y, Wang T, Xu G, Luo G, Zhang M, et al. Integrative proteogenomic and pharmacological landscape of acute myeloid leukaemia. Sci Bull (Beijing). 2025;70:1051\u201356.","DOI":"10.1016\/j.scib.2024.11.020"},{"key":"2925_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molmed.2024.09.004","volume":"31","author":"MD Belew","year":"2025","unstructured":"Belew MD, Chen J, Cheng Z. Emerging roles of cyclin-dependent kinase 7 in health and diseases. Trends Mol Med. 2025;31:138\u201351.","journal-title":"Trends Mol Med"},{"key":"2925_CR26","doi-asserted-by":"publisher","first-page":"GS3-10","DOI":"10.1158\/1538-7445.SABCS21-GS3-10","volume":"82","author":"C Coombes","year":"2022","unstructured":"Coombes C, Howell SJ, Krebs MG, Lord S, Kenny LM, Bahl A, et al. Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Cancer Res. 2022;82:GS3-10.","journal-title":"Cancer Res"},{"key":"2925_CR27","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1158\/1078-0432.CCR-23-2975","volume":"30","author":"C Guarducci","year":"2024","unstructured":"Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer. Clin Cancer Res. 2024;30:1889\u2013905.","journal-title":"Clin Cancer Res"},{"key":"2925_CR28","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1200\/JCO.2023.41.16_suppl.3081","volume":"41","author":"D Juric","year":"2023","unstructured":"Juric D, Richardson DL, Bashir B, Sharma M, Papadopoulos KP, Mathews S, et al. Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC). JCO. 2023;41:3081.","journal-title":"JCO"},{"key":"2925_CR29","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/JCO.2024.42.16_suppl.3078","volume":"42","author":"H Xie","year":"2024","unstructured":"Xie H, El-Khoueiry AB, Alistar AT, Babiker HM, Mahalingam D, Barve MA, et al. A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009). JCO. 2024;42:3078.","journal-title":"JCO"},{"key":"2925_CR30","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/oncolo\/oyad215","volume":"29","author":"E Garralda","year":"2024","unstructured":"Garralda E, Schram AM, Bedard PL, Schwartz GK, Yuen E, McNeely SC, et al. A phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors. Oncologist. 2024;29:e131\u2013e40.","journal-title":"Oncologist"},{"key":"2925_CR31","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1093\/cvr\/cvae084","volume":"120","author":"J Chen","year":"2024","unstructured":"Chen J, Wei J, Xia P, Liu Y, Belew MD, Toohill R, et al. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy. Cardiovasc Res. 2024;120:1024\u201336.","journal-title":"Cardiovasc Res"},{"key":"2925_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10238-014-0305-6","volume":"15","author":"Y Xia","year":"2015","unstructured":"Xia Y, Lin L-Y, Liu M-L, Wang Z, Hong H-H, Guo X-G, et al. Selective inhibition of CDK7 ameliorates experimental arthritis in mice. Clin Exp Med. 2015;15:269\u201375.","journal-title":"Clin Exp Med"},{"key":"2925_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq5091","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen X, Shibu G, Sokolsky BA, Soussana TN, Fisher L, Deochand DK, et al. Disrupting the RNA polymerase II transcription cycle through CDK7 inhibition ameliorates inflammatory arthritis. Sci Transl Med. 2024;16:eadq5091.","journal-title":"Sci Transl Med"},{"key":"2925_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01301-7","volume":"20","author":"Y Wei","year":"2021","unstructured":"Wei Y, Li C, Bian H, Qian W, Jin K, Xu T, et al. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Mol Cancer. 2021;20:5.","journal-title":"Mol Cancer"},{"key":"2925_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s42255-020-0227-4","volume":"2","author":"Z Mi","year":"2020","unstructured":"Mi Z, Song Y, Cao X, Lu Y, Liu Z, Zhu X, et al. Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease. Nat Metab. 2020;2:717\u201331.","journal-title":"Nat Metab"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02925-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02925-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02925-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:26:58Z","timestamp":1778048818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02925-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2925"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02925-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC), Zhongshan Institute for Drug Discovery Animal Center (Zhongshan, China) (Approval No. 2024-01-LJ-01, 2025-02-LJ-01, 2025-02-LJ-01-01). This study did not involve human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}